**NEONATAL MEDICATION PROTOCOLS**

**CEFTAZIDIME**  
Created by: NCCU  
Date for review: Aug 2016

<table>
<thead>
<tr>
<th>DRUG:</th>
<th>CEFTAZIDIME</th>
</tr>
</thead>
<tbody>
<tr>
<td>PRESENTATION:</td>
<td>Vial: 1g</td>
</tr>
</tbody>
</table>
| ACTION & INDICATION: | Third generation cephalosporin antibiotic  
Used to treat infections caused by susceptible organisms with suspected resistance to other antimicrobials  
Treatment of pseudomonas organisms resistant to, or as an alternative to, aminoglycosides |
| DOSE: |  
< 7 days: 30mg/kg/dose 12 hourly  
≥ 7 days: 30mg/kg/dose 8 hourly  
Severe infection:  
< 7 days: 50mg/kg/dose 12 hourly  
≥ 7 days: 50mg/kg/dose 8 hourly |
| PREPARATION: | Use solution prepared in Pharmacy if available  
Diluent: Water for Injections  
Intravenous:  
Add 8.9mL diluent to vial  
= 100mg/mL  
Intramuscular:  
Add 3mL Water for Injections or 1% lignocaine to a vial  
= 260mg/mL |
| ADMINISTRATION: | Intramuscular: As per NCCU policy.  
Intravenous: over 3-5 minutes. |
| ADVERSE EFFECTS: | Hypersensitivity, rash  
Renally excreted – reduce dose in renal impairment  
Colitis – colonisation with C. difficile.  
Phlebitis  
Angioedema  
Anaphylaxis  
Diarrhoea  
Positive Coomb's test (approx. 5% patients), which may interfere with blood cross matching |
| COMMENTS: | NB: CO₂ bubbles, which develop in solution, must be expelled from syringe.  
Discard reconstituted solution immediately after use |
| REFERENCES: | Neofax 2012  
Paediatric Pharmacopoeia 13th Ed Royal Children’s Hospital Melbourne  
BNF for Children 2013  
Australian Injectable Drugs Handbook 5th Ed 2011 |
| DATE: | August 2013 |